Medtronic/Tandem Patent Agreement Paves Way For Diabetes Product Development

14 Jul 2020

Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.

Tandem Diabetes Care, Inc. and Medtronic plc have entered into a non-exclusive patent agreement that applies to existing and new products, enabling the two companies to work together on future diabetes pump technology. Tandem was first on the market to receive US Food and Drug Administration clearance for its integrated infusion pump called t:slim X2 while Medtronic is trailing behind in this device category.

This announcement comes just weeks after Tandem finalized an agreement with Abbott Diabetes Care Inc. to connect their technologies.